ReviewActa biomaterialia2026
Avenues for optimization of cardiac therapeutics by minimally invasive delivery.
Review in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs.European heart journal · 2026Article
- Controlled Delivery of Gasotransmitters for Cardiovascular Therapy: Molecular Mechanisms, Engineered Platforms, and Translational Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the past 20 years, minimally invasive delivery strategies have emerged to bridge the therapeutic gap between highly invasive surgery and less efficient nonsurgical approaches. New, less invasive technologies, including vascular, transendocardial, thoracoscopic, and inhalation delivery methods, can enhance cardiac targeting, promote drug retention, and minimize trauma compared to conventional interventions. Understanding current therapeutic agents, including biomolecules, biomaterials, and medical devices, along with their respective mechanisms, is essential for optimizing minimally invasive delivery strategies. Despite current therapeutic promises, dynamic heart motion and low delivery efficiency hinder the clinical translation of minimally invasive heart repair. Future studies should aim to address these hurdles by optimizing cardiac uptake, advancing personalized medicine, and developing safer delivery tools. To map the state of the field and its future potential, this review summarizes several minimally invasive cardiac delivery approaches and how to leverage existing techniques in concert to harness the impact of minimally invasive cardiac delivery. STATEMENT OF SIGNIFICANCE: Minimally invasive cardiac delivery techniques represent an important advancement in treating heart diseases, bridging the gap between invasive surgeries and less effective nonsurgical methods. Unlike traditional approaches, these novel methods, including vascular, transendocardial, thoracoscopic, and inhalation techniques, provide targeted drug delivery directly to the heart while reducing trauma. This review uniquely synthesizes current advancements in delivering therapeutic agents such as biomolecules and medical devices, highlighting their improved cardiac targeting and retention capabilities. It identifies critical challenges, including the heart's motion and low delivery efficiency, and discusses opportunities for innovation. Addressing these challenges can significantly impact patient outcomes, enhance personalized treatments, and advance the broader field of minimally invasive cardiovascular medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.